Lead Sponsor

Abramson Cancer Center at Penn Medicine

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Participants will be ≥ 18 years of age.
•Histologically proven pancreatic adenocarcinoma. .
•Deemed to have achieved stability following ≥16 weeks of platinum based therapy, in the opinion of an investigator
•Considered a candidate for PARP inhibitor therapy, with or without additional agents, either on a clinical trial or as part of clinical care.
•Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures.

•Females who are pregnant or breast feeding at the time of screening will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential at screening.
•Inability to tolerate imaging procedures in the opinion of an investigator or treating physician
•Serious or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study.